EBS (Biotechnology) Stock Valuation & Fair Value Trading above fair value
EBS (Biotechnology) trades at a blended P/E of 8.7, about 52% below its historical normal valuation, with a forward growth estimate of -23.9% and a PEG of —. Analysts' one-year estimates have been hit 27% of the time.
Valuation flags
- Negative growth forecast
Frequently asked questions
Is EBS overvalued?
At a blended P/E of 8.7 versus its historical normal P/E of 18.2, EBS trades about 52% below its typical valuation. tickerseer currently rates it trading above fair value.
What is EBS's fair value and PEG?
EBS trades at a blended P/E of 8.7 against a historical normal P/E of 18.2, and a forward growth estimate of -23.9%.
Has tickerseer's rating of EBS changed?
tickerseer's rating has been trading above fair value since 2026-07-31.
Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in the paid plan.
It's free, and you can unsubscribe any time. Educational content, not investment advice.